DongKook Pharmaceutical

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • No new derivative trades or additional financial instruments signed in FY2025 compared to prior year
• • Group-wide risk management policies maintained, with financial risk exposures monitored and reported periodically

Management Discussion & Analysis

• • Revenue KRW 926.9B (+14.1% YoY); Operating profit KRW 9.66B (+20.1% YoY); Net income KRW 7.39B (+18.6% YoY)
• • Healthcare segment grew 85% driven by global branding and social media marketing including Instagram and TikTok follower surge

Business Overview

• • Oral disease treatment tablet sales KRW 45.9B with 56.5% market share in 2024 vs 49.6% in 2023
• • Dermatological treatment market share increased to 59.6% in 2024 from 51.1% in 2023

What are the latest DongKook Pharmaceutical DART filings in 2026?

DongKook Pharmaceutical (KRX code 086450) has filed an annual report on March 12, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did DongKook Pharmaceutical file its most recent annual report?

DongKook Pharmaceutical filed its most recent annual report on March 12, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is DongKook Pharmaceutical's KRX stock code?

DongKook Pharmaceutical's KRX stock code is 086450. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 086450 to look up all DongKook Pharmaceutical disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does DongKook Pharmaceutical file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for DongKook Pharmaceutical.

Where can I find DongKook Pharmaceutical financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from DongKook Pharmaceutical annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.